3C Therapeutics
3C Therapeutics develops Degrader-Antibody Conjugate (DAC) therapeutics that combine targeted protein degradation with antibody specificity to address diseases with limited treatment options. The company's platform links degrader molecules to antibodies, with a pipeline targeting oncology and neurodegenerative indications, aiming to expand the druggable proteome beyond traditional small-molecule approaches.
- Drug Discovery & Therapeutics
- Biotechnology
- Healthcare Technology
Funding
Founders
Founder details are not available yet.
Product
Problem
Many disease-driving proteins remain "undruggable" with conventional small molecules or biologics, leaving patients with limited treatment options for serious conditions such as oncology and neurodegenerative disorders. Existing therapeutic modalities often cannot selectively eliminate disease-causing proteins while sparing healthy ones, creating a need for more precise degradation approaches.
Solution
3C Therapeutics develops novel Degrader-Antibody Conjugate (DAC) therapeutics that combine targeted protein degradation with antibody specificity. The platform links degrader molecules to antibodies, enabling cell-specific delivery of protein degradation machinery to disease-relevant targets. This approach aims to expand the druggable proteome by addressing targets previously considered inaccessible to traditional therapeutics. The company's pipeline includes candidates designed to treat oncology and neurodegenerative indications, leveraging the precision of antibody targeting with the potency of degradation mechanisms.
Target Audience
Primary stakeholders are patients with oncology and neurodegenerative diseases who have limited existing treatment options, along with the clinicians and research partners developing therapies for these conditions.
Features
- DAC platform conjugating degrader payloads to antibodies for cell-type-specific protein degradation
- Pipeline candidates targeting oncology and neurodegenerative disease indications
- Technology designed to expand the druggable proteome beyond conventional small-molecule binding sites
- Approach combining the selectivity of antibody-based delivery with the catalytic mechanism of targeted protein degraders